EXHIBIT
10.12

     

    

     

    Dr.
Eugene A. Bauer

    59
Montecito Road

    San
Rafael, California 94901

    


    November
14, 2007

    


    RE: Medgenics, Inc. (the
“Company”)

     

    Dear Dr.
Bauer:

    


    I am
writing to you on behalf of the board of directors of the Company to confirm
arrangements with regard to the terms of your continuation in office as a
director of the Company from the date of this letter.

    


    
      	
              1 

            	
              Definitions

            


    

    


    For the
purposes of this Letter, the following words or expressions shall have the
following meanings respectively:

    


    
      	
              “AIM”

            	
              means
      the AIM Market of London Stock Exchange
plc;

            


    

    


    
      	
              “Biopump”

            	
              means
      a micro organ which has undergone ex-vivo transduction with a vector such
      that it produces and secretes a desired therapeutic
    protein;

            


    

    


    
      	
              “Board”

            	
              means
      the board of directors of the Company, including any committee of the
      Board duly constituted by it;

            


    

    


    
      	
              “Businesses”

            	
              means:

            


    

    


    
      	
            	
              (a)

            	
              the
      business of the research, development, design, production, manufacturing,
      marketing, sale, distribution and other commercial activities of any Group
      Company in relation to the Group’s
      proprietary and/or licensed technology concerning a platform technology
      for the treatment of various diseases and/or chronic disorders and
      conditions whereby a sliver of human dermal tissue is converted into an
      internal protein production plant, through ex vivo transduction with a viral or
      non-viral vector, and the processed tissue is re-implanted under the human
      donor’s
      skin to provide therapeutic levels of protein delivery;
  and

            


    

    


    
      	
               
      

            	
              (b)

            	
              any
      other business that any Group Company shall at the relevant
      date;

            


    


    
      
         


      

      
        
        

        
          

        

      

      
         


      

    


    
      	
               
      

            	
              (i)

            	
              be
      engaged in and with which you shall have been concerned or involved to any
      material extent at any time during Your Appointment;
  or

            


    

    


    
      	
               
      

            	
              (ii)

            	
              have
      determined to carry on with a view to developing any other biotechnical
      technology for commercial exploitation in the future and in relation to
      which determination you shall at the Termination Date possess any material
      Confidential Business Information;

            


    

     

    
      	
              “Confidential
      Business
Information”

            	
              means
      all and any Corporate Information, Marketing Information, Technical
      Information and other information (whether or not recorded in documentary
      form or on computer disk or tape) which the Company or any Group Company
      treats as confidential or in respect of which it owes an obligation of
      confidentiality to any third party, which is not in the public
      domain:

            


    

     

    
      	
               
      

            	
              (a)

            	
              which
      you shall have acquired or shall hereafter acquire at any time during Your
      Appointment but which does not form part of your own stock in trade;
      and

            


    

    


    
      	
               
      

            	
              (b)

            	
              which
      is not readily ascertainable to persons not connected with the Company or
      any Group Company;

            


    

    


    
      	
              “Corporate
      Information”

            	
              means
      all and any information (whether or not recorded in documentary form or on
      computer disk or tape) relating to the business methods, corporate plans,
      management systems, finances, maturing new business opportunities or
      research and development projects of the Company or any Group
      Company;

            


    

    


    
      	
              “DGCL”

            	
              means
      Delaware General Corporation Law;

            


    

    


    
      	
              “Group”

            	
              means
      the Company and its affiliates, including any company that controls, is
      controlled by, or is under common control with the Company, as defined in
      Rule 3b-18 of the Securities Exchange Act of 1934, as amended from time to
      time, including, without limitation to the generality of the foregoing,
      Medgenics Medical (Israel) Limited;

            


    

    


    
      	
              “Group
      Company”

            	
              means
      a member of the Group and “Group
      Companies” shall be
      interpreted accordingly;

            


    

    


    
      	
              “Marketing
      Information”

            	
              means
      all and any information (whether or not recorded in documentary form or on
      computer disk or tape) relating to the marketing or sales of any past
      present or future product or service of the Company or any Group Company
      including, without limitation, sales targets and statistics, market share
      and pricing statistics, marketing surveys and plans, market
      research reports, sales techniques, price lists, discount structures,
      advertising and promotional material, the names, addresses, telephone
      numbers, contact names and identities of customers and potential customers
      of and suppliers and potential suppliers to the Company or any Group
      Company, the nature of their business operations, their requirements for
      any product or service sold to or purchased by the Company or any Group
      Company and all confidential aspects of their business relationship with
      the Company or any Group
Company;

            


    


    
      
         


      

      
        2

        
          

        

      

      
         


      

    


    
      	
              “Material
      Interest”

            	
              means:

            


    

     

    
      	
               
      

            	
              (a)

            	
              the
      holding of any position as director, officer, employee, consultant,
      partner, principal or agent;

            


    

    


    
      	
               
      

            	
              (b)

            	
              the
      direct or indirect control or ownership (whether jointly or alone) of any
      shares (or any voting rights attached to them) or debentures save for the
      ownership for investment purposes only of not more than five percent (5%)
      of the issued shares of any company whose shares are listed on any
      national securities exchange (as defined in Section 3(a)(1) of the
      Securities Exchange Act of 1934, as amended from time to time), or any
      similar exchange in jurisdictions outside the United States, including
      AIM; or

            


    

    


    
      	 	
              (c) 

            	
              the
      direct or indirect provision of any
finance;

            


    

    


    other
than on behalf of any Group Company for the legitimate purposes of that Group
Company;

    


    
      	
              “Technical
      Information”

            	
              means
      all and any trade secrets, secret formulae, processes, inventions,
      designs, know-how discoveries, technical specifications and other
      technical information (whether or not recorded in documentary form or on
      computer disk or tape) relating to the creation, production or supply of
      any past, present or future product or service of the Company or any Group
      Company;

            


    

    


    
      	
              “Termination
      Date”

            	
              means
      the date of the termination of Your Appointment;
  and

            


    

    


    
      	
              “Your
      Appointment”

            	
              means
      your appointment to and holding of office as a director of the Company as
      confirmed by this letter.

            


    

    


    
      	
              2

            	
              Duties

            


    

    


    
      	
              2.1

            	
              As
      the Chairman of the Board and as a director of the Company you will be
      expected to exercise the general fiduciary duties and duties of care and
      loyalty as provided under the DGCL and provide such advice and services as
      the Board may reasonably require.

            


    

    


    
      	
              2.2

            	
              The
      Board as a whole is collectively responsible for the success of the
      Company. The Board's role is to:

            


    

    


    
      	
               
      

            	
              2.2.1

            	
              provide
      entrepreneurial leadership of the Company within a framework of prudent
      and effective controls, which enable risk to be assessed and
      managed;

            


    

    


    
      	
               
      

            	
              2.2.2

            	
              set
      the Group's strategic aims, ensure that the necessary financial and human
      resources are in place for the Company to meet its objectives and review
      management performance; and

            


    

    


    
      	
               
      

            	
              2.2.3

            	
              set
      the Company's values and standards and ensure that its obligations to its
      shareholders and others are understood and
met.

            


    

    


    
      	
              2.3

            	
              In
      your role as a non-executive director, you shall be required
      to:

            


    

    


    
      	
               
      

            	
              2.3.1

            	
              constructively
      challenge and contribute to the development of the Group’s
      strategy;

            


    


    
      
         


      

      
        3

        
          

        

      

      
         


      

    


    
      	
               
      

            	
              2.3.2

            	
              scrutinise
      the performance of management in meeting agreed goals and objectives and
      monitor the reporting of
performance;

            


    

    


    
      	
               
      

            	
              2.3.3

            	
              satisfy yourself
      that financial information is accurate and that financial controls and
      systems of risk management are appropriate, robust and
      defensible;

            


    

    
      
      

    

    


    
      	
               
      

            	
              2.3.4

            	
              endeavour
      to attend all meetings of the Board and the annual and all other meetings
      of the shareholders of the Company;

            


    

    


    
      	
               
      

            	
              2.3.5

            	
              serve
      on the Audit and Remuneration and Nominations committees of the Board and
      attend all such committees’
      meetings;

            


    

    


    
      	
               
      

            	
              2.3.6

            	
              at
      all times comply with the certificate of incorporation and bylaws of the
      Company, each as the same may be amended or restated from time to
      time;

            


    

    


    
      	
               
      

            	
              2.3.7

            	
              abide
      by your fiduciary duties as a director of the
  Company;

            


    

    


    
      	
               
      

            	
              2.3.8

            	
              diligently
      perform your duties;

            


    

    


    
      	
               
      

            	
              2.3.9

            	
              immediately
      report your own wrongdoing or the wrongdoing or proposed wrongdoing of any
      other employee or director of the Company of which you become aware to the
      Chief Executive Officer of the Company;
and

            


    

    


    
      	
            	
              2.3.10

            	
              comply
      with the terms of the “Model Code
      of Practice relating to securities dealings by Company directors and
      certain employees of the Company” adopted by
      the Board this day ( a copy of which is annexed hereto) and any code of
      practice issued by the Company from time to time relating to dealing in
      the Company's securities.

            


    

    


    
      	
              2.4

            	
              In
      addition, in your role as Chairman of the Board, your duties shall require
      that you shall:

            


    

    


    
      	
               
      

            	
              2.4.1

            	
              chair
      meetings of the Board and annual and special meetings of the Company,
      including setting and/or approving the agenda for each such
      meeting;

            


    

    


    
      	
               
      

            	
              2.4.2

            	
              promote
      the highest standards of integrity, probity and corporate governance
      throughout the Company, particularly at Board
  level;

            


    

    


    
      	
               
      

            	
              2.4.3

            	
              use
      your best endeavours to ensure that the Board receives accurate, timely
      and clear information;

            


    

    


    
      	
               
      

            	
              2.4.4

            	
              use
      your best endeavours to ensure effective communication with
      shareholders;

            


    

    


    
      	
               
      

            	
              2.4.5

            	
              use
      your best endeavours to facilitate the effective contribution of
      non-executive directors and to ensure constructive relations are
      maintained between the executive and non-executive
    directors;

            


    

    


    
      	
               
      

            	
              2.4.6

            	
              ensure
      that the performance of the Chief Executive Officer (and of any other
      executive director(s) from time to time) is evaluated at least once a
      year; and

            


    

    


    
      	
               
      

            	
              2.4.7

            	
              at
      the request of the Company, serve on the Company’s Scientific
      Advisory Board.

            


    

     

    
      	
              3

            	
              Time
      Commitment

            


    

    


    You shall
work such hours per week over the term Your Appointment as are necessary for the
proper performance of your duties as Chairman and as a non-executive director of
the Company.


    
      
         


      

      
        4

        
          

        

      

      
         


      

    


    
      	
              4

            	
              FEES

            


    

    


    You will
be entitled to a fee at the rate of ten US Dollars (US$ 10) per annum, if
demanded. The fee will be payable (if demanded) in arrears within thirty (30)
days of the later of the end of the relevant year and the receipt by the Company
of an invoice from you in respect thereof. A year for this purpose shall be a
period commencing on the date hereof or on any first anniversary hereof and
ending 12 consecutive calendar months thereafter. This fee and the terms
prescribing the frequency of payment shall be fixed for a period of one (1) year
following admission of the Company’s issued common
shares to trading on the AIM and thereafter shall be subject to review. On
termination of your appointment you will (if applicable) be paid your
director’s
fee on a pro-rata basis, to the extent unpaid up to the Termination
Date.

    


    
      	
              5

            	
              Term
      of office

            


    

    


    Your
Appointment commenced on March 22, 2001 and shall continue following the date of
this letter unless or until your successor is elected and qualified or until
your earlier resignation or removal. You agree that you will given not less than
sixty (60) days’ (or such lesser
period if agreed by the Board) prior notice in writing to the Company in the
event you wish to resign prior to the expiration of your term or in the event
you do not wish to stand for re-election at the Company’s annual meeting
of stockholders.

    


    For the
avoidance of doubt, by your counter-signature hereto, you acknowledge that your
continuation in office is subject to the DGCL and the certificate of
incorporation and bylaws of the Company, each as the same may be amended or
restated from time to time.

    


    On
termination of Your Appointment for whatever reason you will promptly return to
the Company all documents, records, keys, correspondence or other items in your
possession or under your control which relate in any way to the business or
affairs of, or are the property of, the Company or any Group Company and all
copies thereof, regardless of the medium upon or in which such copies are stored
or held. In addition, you will cease to use the Company’s facilities and
cease to hold yourself out as being a director of the Company.

    


    
      	
              6

            	
              Expenses

            


    

    


    The
Company shall reimburse you in respect of all reasonable travelling, hotel,
entertainment and other out of pocket expenses properly and necessarily incurred
by you in or about the performance of your duties under this Agreement, subject
to the production (if requested) of any receipts, vouchers and other supporting
documentation that the Company shall reasonably require.

    


    
      	
              7

            	
              Confidentiality

            


    

    


    
      	
              7.1

            	
              Both
      during the currency and after the Termination Date, you will treat all
      Confidential Business Information as confidential and not use or disclose
      the same to any other party except:

            


    

    


    
      	
               
      

            	
              7.1.1

            	
              insofar
      as may be necessary for the proper and effective performance of your
      duties as a director of the Company and then only to a person who shall be
      subject to equivalent, express, written confidentiality obligations to the
      Company or a Group Company;

            


    

    


    
      	
               
      

            	
              7.1.2

            	
              to
      the extent that such information is or (without default of your part)
      becomes generally available to the public;
or

            


    

    


    
      	
               
      

            	
              7.1.3

            	
              to
      the extent that you shall be required to disclose the same by any
      applicable law or legally binding order of any court, government,
      semi-governmental authority, administrative or judicial body, or a legally
      binding requirement of a stock exchange or
  regulator.

            


    


    
      
         


      

      
        5

        
          

        

      

      
         


      

    


    
      	
              7.2

            	
              If
      you are required to make a disclosure as contemplated in clause
      7.1.3:

            


    

    


    
      	
               
      

            	
              7.2.1

            	
              you
      must disclose only the
      minimum Confidential Business Information required to comply with the
      applicable law, order or requirement;
and

            


    

    


    
      	
               
      

            	
              7.2.2

            	
              before
      making such disclosure, you must:

            


    

    


    
      	
               
      

            	
              (a)

            	
              give
      the Company reasonable written notice
of:

            


    

    


    
      	
               
      

            	
              (i)

            	
              the
      full circumstances of the requirement for disclosure arising;
      and

            


    

    


    
      	
               
      

            	
              (ii)

            	
              the
      Confidential Business Information which you propose to disclose;
      and

            


    

    


    
      	
               
      

            	
              (b)

            	
              consult
      with the Company as to the form of the
  disclosure.

            


    

    


    
      	
              7.3

            	
              By
      your counter-signature hereto, you acknowledge
  that:

            


    

    


    
      	
               
      

            	
              7.3.1

            	
              the
      Company and each Group Company possess a valuable body of Confidential
      Business Information;

            


    

    


    
      	
               
      

            	
              7.3.2

            	
              the
      Company has given and will continue to give you access to Confidential
      Business Information in order that you may carry out your duties
      hereunder;

            


    

    


    
      	
               
      

            	
              7.3.3

            	
              your
      duties include, without limitation, a duty of care and a duty of loyalty
      as provided under the DGCL; and

            


    

    


    
      	
               
      

            	
              7.3.4

            	
              the
      disclosure of any Confidential Business Information other than for the
      legitimate business purposes of the Company or any Group Company,
      including (without limitation) to an actual or potential competitor of the
      Company or any Group Company could place such company at a serious
      competitive disadvantage and could cause immeasurable (financial and
      other) damage to the Businesses

            


    

    


    and that
the obligations of confidentiality assumed under the provisions of this clause 7
are reasonable and necessary for the protection of the Group, the Businesses and
the Confidential Business Information.

    


    
      	
              8

            	
              Other
      Interests and Restrictions

            


    

    


    
      	
              8.1

            	
              It is accepted and
      acknowledged that you have business interests other than those of the
      Company and that you have declared any potential conflicts that are
      apparent at present. If you become aware of any potential conflicts of
      interest after the date hereof, these should
      be disclosed to the Chief Executive Officer of the Company and company
      secretary as soon as you become aware
      thereof.

            


    

    
    

     

    
      	
              8.2

            	
              By
      your counter-signature hereto, you agree and undertake that, during the
      term of Your Appointment, you shall not, without the Company's written
      permission, assume or hold any Material Interest in any person, firm or
      company which:

            


    

    


    
      	
               
      

            	
              8.2.1

            	
              impairs
      or might reasonably be thought by the Board to impair your ability to act
      at all times in the best interests of the Company;
  or

            


    

    


    
      	
               
      

            	
              8.2.2

            	
              requires
      or might reasonably be thought by the Board to require you to disclose any
      Confidential Business Information in order properly to discharge your
      duties to or to further your interest in such person, firm or
      company.

            


    


    
      
         


      

      
        6

        
          

        

      

      
         


      

    


    
      	
              8.3

            	
              By
      your counter-signature hereto, you agree and undertake that you will not,
      without the Company’s written
      permission, during the term of Your Appointment and for the period of 12
      months after the Termination Date, in any part of the world, whether
      directly or indirectly:

            


    

    


    
      	
               
      

            	
              8.3.1

            	
              assume
      or hold a Material Interest in a business which manufactures, distributes
      or utilizes the Group’s Biopump
      technology using Biopumps;

            


    

    


    
      	
               
      

            	
              8.3.2

            	
              solicit,
      or by any other means induce or seek to induce, any person, firm or
      company with whom or which any Group Company transacts business (whether
      as customer, supplier, contractor, licensor, adviser or otherwise in
      relation to the Business) to cease dealing with such Group Company or to
      restrict or vary the terms upon which it deals with such Group
      Company;

            


    

     

    
      	
               
      

            	
              8.3.3

            	
              solicit
      or entice away or employ or engage or seek to entice away from any Group
      Company any person who is and was at the Termination Date or at any time
      during the six (6) months prior to the Termination Date a director,
      scientific adviser, regulatory adviser, bioscience engineer or other
      scientific, program, product development, marketing, sales, licensing,
      research and development and/or other senior manager, key salesperson or
      secretary (if any) assigned to you;
or

            


    

    


    
      	
               
      

            	
              8.3.4

            	
              enter
      into a license with Yissum Research Development Company of the Hebrew
      University of Jerusalem (“Yissum”) for any of
      the technologies that are currently expressly excluded from the “Scope” of the
      Agreement between Yissum and the Company dated November 23, 2005 (the
      “Yissum
      License”), as set
      forth on Appendix A of the Yissum
License.

            


    

     

    
      	
              8.4

            	
              By
      your counter-signature hereto, you agree and undertake that you will not
      at any time after the Termination Date, represent or hold yourself out or
      permit yourself to be represented or held out by any person, firm or
      company as being in any way then currently connected with or interested in
      the Company or any Group Company other than (if such be the case) as the
      holder of shares, options and/or warrants in the
  Company.

            


    

    


    
      	
              8.5

            	
              Each
      of the provisions of clauses 8.2, 8.3 and 8.4 and (where applicable) the
      sub-clauses thereof is independent and severable from the remaining
      provisions and enforceable accordingly. If any provision of the said
      clauses/sub-clauses shall be unenforceable for any reason but would be
      enforceable if part of the wording thereof were deleted, it shall apply
      with such deletions as may be necessary to make it
      enforceable.

            


    

    


    
      	
              8.6

            	
              You
      have given the undertakings contained in this clause 8 to the Company
      itself and to the Company as trustee for the benefit of each Group Company
      and will, at the request and cost of the Company, promptly enter into
      direct undertakings with any Group Company which correspond to the
      undertakings in this clause 8.

            


    

    


    
      	
              8.7

            	
              The
      Company agrees that each Material Interest that you assume or hold as of
      the date hereof is hereby
permitted.

            


    

    


    
      	
              9

            	
              Independent
      Legal Advice

            


    

    


    Occasions
may arise when you consider that you will need professional advice in connection
with the performance of your duties as a director of the Company and you will be
able to consult the Company’s advisors for
this purpose. Exceptional circumstances may occur when it may be appropriate for
you to seek such advice from independent advisors, at the Company’s expense. In such
an event, you should, where reasonably practical and not (in your reasonable
judgment) prejudicial to the interests of the Company, consult with the Board
or, if you consider appropriate, the non-executive directors, prior to such
advice being sought or expense being incurred.


    
      
         


      

      
        7

        
          

        

      

      
         


      

    


    
      	
              10

            	
              Governing
      law and jurisdiction

            


    

    


    This
Letter shall be governed by and shall be interpreted in accordance with the
DGCL. The parties irrevocably submit to the non-exclusive jurisdiction of the
state courts of Delaware, USA in relation to all matters arising out of or in
connection with this appointment letter.

    


    We took
forward to your continued contribution as a director and I should be grateful if
you would please confirm your acceptance of the terms of your appointment by
signing and returning the duplicate of this Letter.

     

     

     

    
      
        
          
            
              
                
                  	

                          Yours
      sincerely

                        	 
	 	 
	
                            

                        	 
      
	
                          Andrew
      L. Pearlman

                        	 
      
	
                          Director,
      duly authorized for and on behalf of the
Board

                        


                

              

            

          

        

      

    

     

    
      
         


      

      
        8

        
          

        

      

      
         


      

    


    I hereby
acknowledge the above terms and agree and undertake in the above
terms.

    


    
      
        
          
            	
                    SIGNED AS A DEED

                  	
                    )

                  	 
      	 
	
                    by
      Eugene A. Bauer

                  	
                    )

                  	 
      	 
	
                    in
      the presence of:-

                  	
                    )

                  	
                    /s/ Eugene A. Bauer

                  	 
	 
      	 
      	
                    Eugene
      A. Bauer

                  	 


          

        

      

    

    


    
      
        
          
            
              
                
                  
                    
                      
                        	
                                Witness
      Signature:

                              	
                                /s/
      Clarence L. Dellio

                              	 
	 
      	 
      	 
	
                                Name:

                              	
                                Clarence
      L. Dellio

                              	 
	 
      	 
      	 
	
                                Address:

                              	
                                President
      & COO

                              	 
	 
      	
                                Neosil,
      Inc

                              	 
	 
      	
                                5980
      Horton St, Emeryville, CA 94608

                              	 
	 
      	 
      	 
	
                                Occupation:

                              	
                                Businessman

                              	 


                      

                    

                  

                

              

            

          

        

      

    


    
      
         


      

      
        9

        
          

        

      

      
         


      

    


    Annex

     

    July
2007

     

    
      
        

      

       

      MODEL
CODE OF PRACTICE

    

     

    RELATING
TO

     

    SECURITIES
DEALINGS

     

    BY
COMPANY DIRECTORS AND CERTAIN EMPLOYEES

     

    OF
MEDGENICS, INC.

     

    
      

    
 

    
      
         


      

      
        10

        
          

        

      

      
         


      

    


    Medgenics,
Inc. (the “Company”) has adopted the
following code for transactions in securities by directors, applicable employees
and persons connected with them (the “Code”). Directors,
applicable employees and persons connected with them should consider carefully
the application of the Code prior to any dealings in the securities in the
Company. Directors, applicable employees and persons connected with them should
note however that:

    


    
      	
              (a)

            	
              Under
      the Criminal Justice Act 1993, it is a criminal offence for an individual
      who has information as an insider to deal on a regulated market, or
      through or as a professional intermediary, in securities whose price would
      be significantly affected if the inside information were made public. It
      is also an offence to encourage insider dealing and to disclose inside
      information with a view to others profiting from
  it.

            


    

    


    
      	
              (b)

            	
              The
      Financial Services and Markets Act 2000 (“FSMA”) introduced a civil
      offence regime relating to market abuse, which supplements the existing
      offences of insider dealing and market manipulation/misleading statements
      offences under the FSMA. The offence, which also applies to securities
      traded on AIM, applies:

            


    

    


    
      	
               
      

            	
              (i)

            	
              where
      there is behaviour (including anything said, done or written, or not)
      including misuse of non public information, misleading the market or
      distorting the market; and

            


    

    


    
      	
               
      

            	
              (ii)

            	
              which
      falls below the standard of behaviour that a regular user of the relevant
      market would reasonably expect of a person in the same position as whoever
      is committing the offence in relation to that
  market.

            


    

     

    
      	
              (c)

            	
              Encouraging
      someone else to engage in market abuse is also an offence. The offence
      applies to any person (corporates as well as individuals), it can catch
      behaviour outside the UK, it is purely effect-based (no intention is
      required) and no transaction is
required.

            


    

    


    
      	
              (d)

            	
              The
      Financial Services Authority (“FSA”) has powers
      to impose an unlimited fine or make a public statement about market abuse
      and to apply for court orders to remedy instances of market abuse. The FSA
      Code of Conduct sets out the FSA's opinion on behaviour it considers is/is
      not, market abuse and the facts it will take into account when determining
      the question.

            


    

    


    
      	
              (e)

            	
              You
      must take care before any form of dealing in the Company's securities and
      where appropriate, consult the Company's nominated adviser or solicitors.
      For example, a dealing which may fall outside the Code might still
      constitute an offence under insider dealing or market abuse
      legislation.

            


    

    


    
      	
              (f)

            	
              This
      document addresses the share dealing restrictions set out in the AIM Rules
      for Companies alone. Its purpose is to ensure that Directors, applicable
      employees and their families do not abuse, or place themselves under
      suspicion of abusing, price-sensitive information that they may have or be
      thought to have, especially in periods leading up to an announcement of
      results.

            


    

    


    
      	
              (g)

            	
              A
      Director is also under an obligation to notify the Company in writing of
      his or her interests (and of the interests of persons connected with him
      or her) from time to time in its securities (within the meaning of the AIM
      Rules for Companies). A Director must disclose to the Company all
      information known to him or her (or which he or she could with reasonable
      diligence ascertain) which it needs in order to comply with that
      obligation. You must take care and where appropriate consult the Company's
      nominated adviser or solicitor. For example, a dealing which may fall
      outside the Code might still need to be disclosed to the
      Company.

            


    


    
      
         


      

      
        11

        
          

        

      

      
         


      

    


    
      	
              (h)

            	
              The
      preceding introduction and the paragraph headings in this document, do not
      form part of the Code, are for guidance and ease of reference only and are
      not to be construed as affecting the substance or interpretation of the
      Code.

            


    

    


    
      	
              (i)

            	
              Compliance
      with the Code may not constitute a defence to any charge under applicable
      law.

            


    

    


    If
there is any doubt as to the application of the Code, the Company's nominated
adviser should be consulted by the Company at an early stage.

    


    Definitions

    


    
      	
              1

            	
              In
      this Code the following definitions, in addition to those contained in the
      Rules, apply unless the context otherwise
  requires:

            


    

    


    
      	
               
      

            	
              “AIM”

            	
              means
      the AIM Market operated by the
Exchange;

            


    

    


    
      	
            	
              “AIM Rules for
Companies”
      or
“Rules”

            	
              means
      the AIM Rules for Companies published by the Exchange (as amended from
      time to time);

            


    

    


    
      	
               
      

            	
              “AIM
      Securities”

            	
              means
      securities of a class which have been admitted to AIM effected by a
      dealing notice under rule 6 of the AIM Rules for
  Companies;

            


    

    


    
      	
            	
              “applicable
      employee”

            	
              means
      any employee of the Company or of a subsidiary undertaking or parent
      undertaking of the Company who, because of his office or employment in the
      Company or subsidiary undertaking or parent undertaking, is likely to be
      in possession of unpublished price-sensitive information in relation to
      the Company;

            


    

    


    
      	
               
      

            	
              “close
      period”

            	
              means
      any of the periods when a director is prohibited from dealing as specified
      in paragraph 3 of this Code;

            


    

    


    
      	
               
      

            	
              the
      “Company”

            	
              means
      Medgenics, Inc., (registered in the State of Delaware whose registered
      office is at 2711 Centreville Road, Suite 400, in the City of Wilmington,
      19808, County of New Castle, Delaware,
USA);

            


    

    


    
      	
               
      

            	
              “dealing”

            	
              means
      any change whatsoever to the holding of securities of the Company where
      the holder is a director, applicable employee or person connected with
      them and includes any acquisition or disposal of, or agreement to acquire
      or dispose of any securities of the Company and the grant, acceptance,
      acquisition, disposal, exercise or discharge of any option (whether for
      the call, or put, or both) or other right or obligation, present or
      future, conditional or unconditional, to acquire or dispose of securities,
      or any interest in securities, of the Company and “deal”
      shall be construed accordingly;

            


    

    


    
      	
               
      

            	
              “Exchange”

            	
              means
      London Stock Exchange Plc;

            


    

    


    
      	
               
      

            	
              “Holdings”

            	
              means
      any legal or beneficial interest, direct or
  indirect;

            


    

    


    
      	
               
      

            	
              “prohibited
      period”

            	
              means
      any period to which paragraph 6 of this Code
  applies;

            


    


    
      
         


      

      
        12

        
          

        

      

      
         


      

    


    
      	
               
      

            	
              “securities”

            	
              means
      any AIM Securities or any securities that are convertible into AIM
      Securities and, where relevant, securities which have been quoted in a
      member state or admitted to dealing on, or have their prices quoted on or
      under the rules of, any regulated market, or any unquoted securities that
      are convertible into such
securities;

            


    

    


    
      	
            	
              “unpublished
      price-
sensitive information”

            	
              means
      information which:

            


    

    


    
      	
               
      

            	
              (i)

            	
              relates
      to particular securities or to a particular issuer or to particular
      issuers of securities and not to securities generally or issuers of
      securities generally (and, for these purposes, information shall be
      treated as relating to an issuer of securities which is a company not only
      where it is about the Company but also where it may affect the Company's
      business prospects);

            


    

    


    
      	
               
      

            	
              (ii)

            	
              is
      specific or precise;

            


    

    


    
      	
               
      

            	
              (iii)

            	
              has
      not been made public within the meaning of section 58 of the Criminal
      Justice Act 1993; and

            


    

    


    
      	
               
      

            	
              (iv)

            	
              if
      it were made public would be likely to have a significant effect on the
      price or value of any securities,

            


    

    


    and,
without prejudice to the generality of the above, it should be considered
whether any unpublished information regarding transactions required to be
notified to the Regulatory Information Service in accordance with the Rules and
unpublished information of the kind referred to in the paragraphs of the Rules
set out below is price-sensitive:

    


    
      	
               
      

            	
              11

            	
              General
      disclosure of price sensitive
information

            


    

     

    
      	
               
      

            	
              12
      to 16

            	
              Disclosure
      of corporate transactions

            


    

     

    
      	
               
      

            	
              17

            	
              Disclosure
      of miscellaneous information

            


    

    


    
      	
               
      

            	
              “regulated
      market”

            	
              means
      any regulated market defined as such in the Insider Dealing (Securities
      and Regulated Markets) Order 1994, as amended or supplemented by any
      further order made under section 60(1) of the Criminal Justice Act
      1993.

            


    

     

    Dealings
by directors and applicable employees

     

    Purpose
of dealing

    


    
      	
              2

            	
              A
      director or applicable employee must not deal in any securities of the
      Company on considerations of a short term nature. A director must take
      reasonable steps to prevent any dealings by or on behalf of any person
      connected with him in any securities of the Company on considerations of a
      short term nature.

            


    

    


    Dealing
in close periods

    


    
      	
              3

            	
              A
      director or applicable employee or persons connected with them must not
      deal in any securities of the Company during a “close period”.

            


    


    
      
         


      

      
        13

        
          

        

      

      
         


      

    


    A close
period is:

     

    
      	
               
      

            	
              3.1

            	
              the
      period of two months immediately preceding the publication of the
      Company's annual results or, if shorter, the period from its financial
      year end up to and including the time of publication;
  and

            


    

    


    
      	
               
      

            	
              3.1.1

            	
              if
      the Company reports on a half-yearly basis the period of two months
      immediately preceding the notification of its half-yearly report in
      accordance with Rule 18 of the Rules to the Regulatory Information Service
      or, if shorter, the period from the relevant financial period end up to
      and including the time of such notification;
or

            


    

    


    
      	
               
      

            	
              3.1.2

            	
              if
      the Company reports on a quarterly basis, the period of one month
      immediately preceding the notification of its quarterly results or, if
      shorter, the period from the relevant financial period end up to and
      including the time of the notification (save that for the final quarter
      paragraph 3.1 of this Code applies);
or

            


    

    


    
      	
               
      

            	
              3.2

            	
              any
      other period when the Company is in possession of unpublished price
      sensitive information; or

            


    

    


    
      	
               
      

            	
              3.3

            	
              any
      time it has become reasonably probable that such information will be
      required by this Code and/or the Rules to be
  notified.

            


    

    


    
      	
              4

            	
              A
      director or applicable employee must not deal in any securities of the
      Company at any time when he is in possession of unpublished
      price-sensitive information in relation to those securities, or otherwise
      where clearance to deal is not given under paragraph 5 of this
      Code.

            


    

    


    Clearance
to deal

    


    
      	
              5

            	
              A
      director or applicable employee or persons connected with them must not
      deal in any securities of the Company without advising the chairman (or
      one or more other directors designated for this purpose) in advance and
      receiving clearance. In his own case, the chairman, or other designated
      director, must advise the board in advance at a board meeting, or advise
      another designated director, and receive clearance from the board or
      designated director, as
appropriate.

            


    

    


    Circumstances
for refusal

    


    
      	
              6

            	
              A
      director or applicable employee or persons connected with them must not be
      given clearance (as required by paragraph 5 of this Code) to deal in any
      securities of the Company during a prohibited
  period.

            


    

    


    A "prohibited period"
means:

     

    
      	
               
      

            	
              6.1

            	
              any
      close period;

            


    

    


    
      	
               
      

            	
              6.2

            	
              any
      period when there exists any matter which constitutes unpublished price
      sensitive information in relation to the Company's securities (whether or
      not the director has knowledge of such matter) and the proposed dealing
      would (if permitted) take place after the time when it has become
      reasonably probable that an announcement will be required in relation to
      that matter; or

            


    

    


    
      	
               
      

            	
              6.3

            	
              any
      period when the person responsible for the clearance otherwise has reason
      to believe that the proposed dealing is in breach of this
      Code.

            


    


    
      
         


      

      
        14

        
          

        

      

      
         


      

    


    
      	
              7

            	
              A
      written record must be maintained by the Company of the receipt of any
      advice received from a director or applicable employee pursuant to
      paragraph 5 of this Code and of any clearance given. Written confirmation
      from the Company that such advice and clearance (if any) have been
      recorded must be given to the director or applicable employee
      concerned.

            


    

    


    Dealing
in exceptional circumstances

    


    
      	
              8

            	
              Pursuant
      to Rule 21, the Exchange may give clearance to a director or applicable
      employee to sell (but not to purchase) securities when he would otherwise
      be prohibited from doing so in order to alleviate severe personal
      hardship.

            


    

    


    Director
acting as trustee

    


    
      	
              9

            	
              Where
      a director or applicable employee is a sole trustee (other than a bare
      trustee), the provisions of this Code will apply, as if he were dealing on
      his own account. Where a director or applicable employee is a co-trustee
      (other than a bare trustee), he must advise his co-trustees of the name of
      the company of which he is a director or applicable employee. If the
      director or applicable employee is not a beneficiary, a dealing in his
      company's securities undertaken by that trust will not be regarded as a
      dealing by the director or applicable employee for the purposes of this
      Code, where the decision to deal is taken by the other trustees acting
      independently of the director or applicable employee or by investment
      managers on behalf of the trustees. The other trustees or the investment
      managers will be assumed to have acted independently of the director or
      applicable employee for this purpose where
they:

            


    

    


    
      	
               
      

            	
              9.1

            	
              have
      taken the decision to deal without consultation with, or other involvement
      of, the director or applicable employee concerned;
  or

            


    

    


    
      	
               
      

            	
              9.2

            	
              if
      they have delegated the decision making to a committee of which the
      director or applicable employee is not a
member.

            


    

    


    Dealings
by connected persons and investment managers

    


    
      	
              10

            	
              A
      director or applicable employee must (so far as is consistent with his
      duties of confidentiality to his company) seek to prohibit (by taking the
      steps set out in paragraph 11 of this Code) any dealing in securities of
      the Company during a close period or at a time when the director or
      applicable employee is in possession of unpublished price sensitive
      information in relation to those securities and would be prohibited from
      dealing under paragraph 6.1.2 of this
Code:

            


    

    


    
      	
               
      

            	
              10.1

            	
              by
      or on behalf of any person connected with him;
  or

            


    

    


    
      	
               
      

            	
              10.2

            	
              by
      an investment manager on his behalf or on behalf of any person connected
      with him where either he or any person connected with him has funds under
      management with that investment manager, whether or not discretionary
      (save as provided in paragraphs 9 and 17 of this
  Code).

            


    

    


    
      	
              11

            	
              For
      the purposes of paragraph 10 of this Code, a director or applicable
      employee must advise all such connected persons and investment
      managers:

            


    

    


    
      	
               
      

            	
              11.1

            	
              of
      the name of the Company of which he is a director or applicable
      employee;

            


    

    


    
      	
               
      

            	
              11.2

            	
              of
      the close periods during which they cannot deal in the Company's
      securities;

            


    


    
      
         


      

      
        15

        
          

        

      

      
         


      

    


    
      	
               
      

            	
              11.3

            	
              of
      any other periods when the director or applicable employee knows he is not
      himself free to deal in securities of the Company under the provisions of
      this Code unless his duty of confidentiality to the Company prohibits him
      from disclosing such periods; and

            


    

    


    
      	
               
      

            	
              11.4

            	
              that
      they must advise him immediately after they have dealt in securities of the
      Company (save as provided in paragraphs 9 and 17 of this
      Code).

            


    

    


    Special
circumstances

    


    Awards
of securities and options

    


    
      	
              12

            	
              Subject
      to paragraph 13 below, the award of securities, the grant of options and
      the grant of rights (or other interests) to acquire securities in the
      Company to directors and/or applicable employees of the Company is
      permitted in a prohibited period
if:

            


    

    


    
      	
               
      

            	
              12.1

            	
              the
      award or grant is made under the terms of an employees’ share
      scheme;

            


    

    


    
      	
               
      

            	
              12.2

            	
              the
      terms of such employees' share scheme set
out:

            


    

    


    
      	
               
      

            	
              12.2.1

            	
              the
      timing of the award or grant and such terms have
  either:

            


    

    


    
      	
               
      

            	
              12.2.1.1

            	
              previously
      been approved by shareholders or summarised or described in a document
      sent to shareholders, or

            


    

    


    
      	
               
      

            	
              12.2.1.2

            	
              the
      timing of the award or grant is in accordance with the timing of previous
      awards or grants under the scheme;
and

            


    

    


    
      	
               
      

            	
              12.2.2

            	
              the
      amount or value of the award or grant or the basis on which the amount or
      value of the award or grant is calculated;
and

            


    

    


    
      	
               
      

            	
              12.3

            	
              the
      failure to make the award or grant would be likely to indicate that the
      Company is in a prohibited period.

            


    

    


    In
cases of doubt the Company’s nominated
adviser should be consulted.

    


    
      	
              13

            	
              The
      following dealings are not covered by paragraph 12 and are consequently
      subject to the provisions of this Code, unless they fall within paragraph
      20.8 below:

            


    

    


    
      	
               
      

            	
              13.1

            	
              a
      discretionary award or grant under an employees' share scheme, which would
      not otherwise have been made but for the event that led to the
      commencement of the prohibited period;
and

            


    

    


    
      	
               
      

            	
              13.2

            	
              an
      award or grant under an employees' share scheme which is made in a
      prohibited period during which the relevant scheme was introduced, or in
      the case of an existing scheme, the relevant scheme was
      amended.

            


    

    


    Exercise
of options

    


    
      	
              14

            	
              The
      chairman or other designated director may allow the exercise of an option
      or right under an employees’ share
      scheme, or the conversion of a convertible security, where the final date
      for the exercise of such option or right, or conversion of such security,
      falls during any prohibited period and the director could not reasonably
      have been expected to exercise it at an earlier time when he was free to
      deal (see also paragraph 20.8).

            


    

    


    
      	
              15

            	
              Where
      an exercise or conversion is permitted pursuant to paragraph 14 or 20.8 of
      this Code, the chairman or other designated director may not, however,
      give clearance for the sale of securities acquired pursuant to such
      exercise or conversion.

            


    


    
      
         


      

      
        16

        
          

        

      

      
         


      

    


    
      Qualification
shares

    

    


    
      	
              16

            	
              The
      chairman or other designated director may allow a director to acquire
      qualification shares without regard to the provisions of this Code where,
      under the Company’s articles
      of association, the final date for acquiring such shares falls during a
      prohibited period and the director could not reasonably have been expected
      to acquire those shares at another
time.

            


    

    


    Saving
schemes

    


    
      	
              17

            	
              A
      director or applicable employee may enter into a scheme in which only the
      securities of the Company are purchased pursuant to a regular standing
      order or direct debit or by regular deduction from the director or
      applicable employee's salary, or where such securities are acquired by way of a standing election to
      re-invest dividends or other distributions received, or are acquired as
      part payment of a director or applicable employee’s
      remuneration without regard to the provisions of the Code, if the
      following provisions are complied
with:

            


    

    


    
      	
               
      

            	
              17.1

            	
              the
      director or applicable employee does not enter into the scheme during a
      prohibited period, unless the scheme involves the part payment of
      remuneration in the form of securities and is entered into upon the
      director's appointment to the board or the commencement of the applicable
      employee's employment;

            


    

    


    
      	
               
      

            	
              17.2

            	
              the
      director or applicable employee does not carry out the first purchase of
      securities of the Company under the scheme during a prohibited period,
      unless the director or applicable employee is irrevocably bound under the
      terms of the scheme to carry out the first purchase of securities at a
      fixed point in time which falls in a prohibited
  period;

            


    

    


    
      	
               
      

            	
              17.3

            	
              the
      director or applicable employee does not cancel or vary the terms of his
      participation, or carry out sales of the securities of the Company within
      the scheme during a prohibited period;
and

            


    

    


    
      	
               
      

            	
              17.4

            	
              before
      entering into the scheme or cancelling the scheme or varying the terms of
      his/her participation or carrying out sales of the securities of the
      Company within the scheme, the director or applicable employee obtains
      clearance under paragraph 5 of this
Code.

            


    

    


    
      	
              18

            	
              The
      provisions of this Code do not apply to an investment by a director or
      applicable employee in a scheme or arrangement where the assets of the
      scheme or arrangement are invested at the discretion of a third party or
      to a dealing by the director or applicable employee in the units of an
      authorised unit trust or in shares in an open ended investment company. In
      the case of a scheme investing only in the securities of the Company the
      provisions of paragraph 17 of this Code
apply.

            


    

    


    Guidance
on other dealings

    


    
      	
              19

            	
              For
      the avoidance of doubt, and subject to the specific exceptions set out in
      paragraph 20 below, the following constitute dealings for the purposes of
      this Code and are consequently subject to the provisions of this
      Code:

            


    

    


    
      	
               
      

            	
              19.1

            	
              dealings
      between directors and/or applicable
employees;

            


    

    


    
      	
               
      

            	
              19.2

            	
              off-market
      dealings;

            


    

    


    
      	
               
      

            	
              19.3

            	
              transfers
      for no consideration by a director or applicable employee other than
      transfers where the director or applicable employee retains a beneficial
      interest

            


    


    
      
         


      

      
        17

        
          

        

      

      
         


      

    


    
      	
               
      

            	
              19.4

            	
              entering
      into, or terminating, assigning or novating any stock lending agreement in
      respect of securities of the
Company;

            


    

    


    
      	
               
      

            	
              19.5

            	
              using
      as security, or otherwise granting a charge, lien or other encumbrance
      over, securities of the Company;
and

            


    

    


    
      	
               
      

            	
              19.6

            	
              any
      transaction, or the exercise of any power or discretion, effecting a
      change in the ownership of a beneficial interest in securities of the
      Company.

            


    

    


    
      	
              20

            	
              For
      the avoidance of doubt, and notwithstanding the definition of dealing
      contained in paragraph 1 of this Code, the following dealings are not
      subject to the provisions of this
Code:

            


    

    


    
      	
               
      

            	
              20.1

            	
              undertakings
      or elections to take up entitlements under a rights issue or other offer
      (including an offer of shares in lieu of a cash
  dividend);

            


    

    


    
      	
               
      

            	
              20.2

            	
              the
      take up of entitlements under a rights issue or other offer (including an
      offer of shares in lieu of a cash
dividend);

            


    

    


    
      	
               
      

            	
              20.3

            	
              allowing
      entitlements to lapse under a rights issue or other offer (including an
      offer of shares in lieu of a cash
dividend);

            


    

    


    
      	
               
      

            	
              20.4

            	
              the
      sale of sufficient entitlements nil-paid to allow take up of the balance
      of the entitlements under a rights
issue;

            


    

    


    
      	
               
      

            	
              20.5

            	
              undertakings
      to accept, or the acceptance of, a takeover
  offer;

            


    

    


    
      	
               
      

            	
              20.6

            	
              transfers
      of shares arising out of the operation of an employees' share scheme into
      a saving scheme investing only in securities of the Company
      following:

            


    

    


    
      	
               
      

            	
              20.6.1

            	
              exercise
      of an option under a savings related share option scheme;
    or

            


    

     

    
      	
               
      

            	
              20.6.2

            	
              release
      of shares from a profit sharing
scheme;

            


    

    


    
      	
               
      

            	
              20.7

            	
              with
      the exception of a disposal of securities received by a director or
      applicable employee as a participant, dealings in
      connection with an Inland Revenue approved “Save-as-you-earn” share
      option scheme, or any other employees’ share
      scheme under which participation is extended, on similar terms to those
      contained in an Inland Revenue approved “Save-as-you-earn” share
      option scheme, to all or most employees of the participating companies in
      that scheme;

            


    

    


    
      	
               
      

            	
              20.8

            	
              with
      the exception of a disposal of securities received by a director or
      applicable employee as a participant, dealings in connection with an
      Inland Revenue approved profit share scheme, or any similar profit share
      scheme under which participation is extended, on similar terms to those
      contained in an inland Revenue approved profit share scheme, to all or
      most employees of the participating companies in that
    scheme;

            


    

    


    
      	
               
      

            	
              20.9

            	
              the
      cancellation or surrender of an option under an employees’ share
      scheme;

            


    

    


    
      	 	
              20.10

            	
              transfers
      of securities by an independent trustee of an employees’ share
      scheme to a beneficiary who is not a director or an applicable employee;
      and

            


    

    


    
      	 	
              20.11

            	
              bona
      fide gifts to a director or applicable employee by a third
      party.

            


    


    
      
         


      

      
        18

        
          

        

      

      
         


      

    


    Applicable
employees

    


    
      	
              21

            	
              If
      not specifically included in a provision of this Code applicable employees
      must comply with the terms of this Code as though they were
      directors.

            


    


    
      
         


      

      
        19